Skip to Content

Varubi Approval History

FDA Approved: Yes (First approved September 1, 2015)
Brand name: Varubi
Generic name: rolapitant
Dosage form: Tablets and Injection
Company: Tesaro Inc.
Treatment for: Nausea/Vomiting, Chemotherapy Induced

Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.

Development History and FDA Approval Process for Varubi

DateArticle
Oct 25, 2017Approval Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
Sep  2, 2015Approval FDA Approves Varubi (rolapitant) for Chemotherapy-Induced Nausea and Vomiting
Sep  8, 2014Tesaro Announces Submission of Rolapitant NDA to U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide